Procyon Advisors LLC Sells 544 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Procyon Advisors LLC cut its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 13.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,481 shares of the biopharmaceutical company's stock after selling 544 shares during the quarter. Procyon Advisors LLC's holdings in Regeneron Pharmaceuticals were worth $2,479,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the stock. Rakuten Securities Inc. boosted its stake in Regeneron Pharmaceuticals by 380.0% during the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 19 shares during the last quarter. FSA Wealth Management LLC bought a new position in shares of Regeneron Pharmaceuticals during the third quarter valued at $26,000. Fairfield Financial Advisors LTD purchased a new stake in shares of Regeneron Pharmaceuticals during the third quarter valued at $37,000. Truvestments Capital LLC bought a new stake in Regeneron Pharmaceuticals in the 3rd quarter worth about $39,000. Finally, Itau Unibanco Holding S.A. purchased a new position in Regeneron Pharmaceuticals in the 2nd quarter worth about $42,000. Hedge funds and other institutional investors own 83.31% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Wells Fargo & Company dropped their price target on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating on the stock in a report on Friday, January 10th. Wolfe Research initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Friday, November 15th. They issued an "outperform" rating and a $1,150.00 target price for the company. Morgan Stanley lowered their price target on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an "overweight" rating on the stock in a report on Friday, November 1st. UBS Group downgraded shares of Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and dropped their price objective for the stock from $1,130.00 to $738.00 in a report on Thursday. Finally, JPMorgan Chase & Co. reduced their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an "overweight" rating for the company in a research note on Thursday, October 24th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $1,015.38.

Regeneron Pharmaceuticals Price Performance

Shares of REGN traded down $11.65 during midday trading on Friday, hitting $681.58. 1,107,622 shares of the company traded hands, compared to its average volume of 678,713. The stock has a market cap of $74.90 billion, a price-to-earnings ratio of 16.87, a PEG ratio of 1.60 and a beta of 0.10. The firm has a 50 day moving average of $738.60 and a 200-day moving average of $949.99. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. Regeneron Pharmaceuticals, Inc. has a 52 week low of $666.25 and a 52 week high of $1,211.20.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.